Vericel Q2 revenue up 20% to $63.2mln, MACI revenue up 21% to $53.5mln.

• Vericel reports Q2 2025 financial results • Total revenue growth of 20% to $63.2 million • MACI revenue growth of 21% to $53.5 million • Gross margin increased by 400 basis points to 74% • Adjusted EBITDA growth of 112% to $13.4 million • Approximately 600 MACI arthro surgeons trained to date • Received FDA IND clearance for Phase 3 MACI ankle clinical study

Vericel Corporation (NASDAQ: VCEL), a leading provider of advanced therapies for the sports medicine and severe burn care markets, reported robust financial results for the second quarter of 2025. The company's total revenue grew by 20% to $63.2 million, driven primarily by its flagship product, MACI, which saw revenue growth of 21% to $53.5 million. This represents 85% of the total revenue, highlighting MACI's significant role in Vericel's financial performance.

Vericel's gross margin expanded by over 400 basis points to 74%, while adjusted EBITDA grew by 112% to $13.4 million. The company's adjusted EBITDA margin increased by over 900 basis points to 21%, demonstrating exceptional operational leverage as revenue scaled. These improvements indicate a strong profitability trajectory.

Notable operational highlights include the training of approximately 600 MACI Arthro surgeons and the receipt of FDA IND clearance for the MACI Ankle clinical study. The company also achieved the highest number of Epicel biopsies since 2023, with a 38% increase in Epicel revenue. NexoBrid revenue increased by 52% year-over-year, with June marking the highest number of hospital unit orders since its launch.

Vericel maintains a strong financial position with approximately $164 million in cash and investments and no debt. The company's balance sheet provides ample resources for continued growth investments. Management's decision to accelerate the MACI sales force expansion signals confidence in the product's continued momentum.

Vericel reaffirmed its 2025 guidance for MACI revenue growth in the low 20% range, along with expectations for 74% gross margin and 26% adjusted EBITDA margin for the full year. These figures indicate the company's confidence in its strong execution and future prospects.

Vericel's Q2 results show impressive growth with 20% revenue increase, 112% EBITDA growth, and strong MACI adoption driving profitability. The company's operational efficiency and market traction for MACI suggest a promising future for Vericel.

References:
[1] https://www.stocktitan.net/news/VCEL/vericel-reports-second-quarter-2025-financial-4vgwjwc4nkh7.html